Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Living Cell Technologies’ (LCT) CEO, Dr Ken Taylor, has revealed that he plans to retire from his position this year
  • During Dr Taylor’s seven-year tenure as CEO, the company conducted clinical studies and project work for various health treatments
  • Dr Taylor will retire from his role as the company’s CEO sometime in July
  • Until then, he will work with LCT’s board and management to help the company transition to its next phase
  • Living Cell Technologies is in the grey, trading at 1.7 cents per share

Living Cell Technologies’ (LCT) CEO, Dr Ken Taylor, has revealed that he plans to retire from his position this year.

He notified the company’s Board of Directors of his decision today, during a board meeting.

Dr Taylor has led the company for almost seven years, after joining LCT as its new CEO in February 2014. He was appointed to the company’s board in August of the same year.

LCT’s Chairman, Professor Bernie Tuch, described how the company has benefited from Dr Taylor’s connections and reputation in the global pharmaceutical industry.

“During Ken’s seven years in the role, the company has completed two clinical studies of NTCELL as a novel treatment for Parkinson’s disease, and initiated new projects for innovative treatments for migraines and obesity,” he said.

“Due to his extensive professional networks, Ken was able to connect LCT with relevant international experts as well as bring a number of sizeable new investors to the table. We will miss his expertise, insights, and wealth of experience,” he added.

Dr Taylor also commented on his impending retirement, after reflecting on his tenure as LCT’s CEO.

“I have greatly enjoyed the challenges and opportunities during my time with LCT, and am proud of the work of the team I lead,” he said.

“Over the next six months, I will work with the board and management to assist the company in transitioning to its next phase,” he added.

Dr Taylor will officially retire from his role as the company’s CEO sometime in July 2021. 

Living Cell Technologies is in the grey and trading at 1.7 cents per share at 3:36 pm AEDT.

LCT by the numbers
More From The Market Herald

" Anatara Lifesciences (ASX:ANR) expands eligibility criteria for IBS and psychological functioning trials

Anatara Lifesciences (ASX:ANR) has received ethics approval to expand eligibility criteria for its Irritable Bowel Syndrome…

" Althea (ASX:AGH) enters Irish medicinal cannabis market

Althea (ASX:AGH) has received approval from the Health Products Regulatory Authority (HPRA) for its CBD12:THC10 product…

" Apiam Animal Health (ASX:AHX) executes growth strategy with two acquisitions

Apiam Animal Health (ASX:AHX) has announced new acquisitions as part of its growth strategy to double…

" Next Science (ASX:NXS) appoints Oraderm Pharmaceuticals as BlastX distributor

Next Science (ASX:NXS) has signed a multi-year distribution agreement for the sale and distribution of its…